Chemotherapy is one of the most common types of treatment that
fights the symptoms and avert the development of the mesothelioma cancer, as well as
other types of cancer. However, most of the time, the tumors tend to fight off
the effects of the drugs, thus, treatment becomes of no use at all. A recent
study, however, can reveal the reason why cancer cells tend to resist cisplatin,
a common chemotherapeutic agent. This finding can be very helpful in devising a
brand-new treatment strategy not only for mesothelioma, but also for other
types of cancers, that seemingly resist treatments.
Cisplatin is used together with other chemotherapy agents following
surgery to slow down, if not prevent, the growth of the cancer, as well as to alleviate mesothelioma symptoms. However, Guido Kroemer, M.D., Ph.D.,
professor at University Paris Descartes in Paris, France reveals that a lot of patients
would respond transiently to cisplatin therapy.
“Cancer cells develop ways to resist the effects of the drug,”
he reveals